Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2022-06-06 Purchase |
2022-06-07 4:33 pm |
Cullinan Oncology Inc. | CGEM | AHMED NADIM President and CEO |
8,090 | $12.4 | $100,316 | 8,090 (Direct) |
View |
| 2022-06-01 Purchase |
2022-06-03 6:24 pm |
Cullinan Oncology Inc. | CGEM | BVF PARTNERS L P BIOTECHNOLOGY VALUE FUND L P BVF I GP LLC BIOTECHNOLOGY VALUE FUND II LP BVF II GP LLC Biotechnology Value Trading Fund OS LP BVF Partners OS Ltd. BVF GP HOLDINGS LLC BVF INC LAMPERT MARK N 10% Owner |
751,396 | $11 | $8,264,905 | 364,161 (Direct) |
View |
| 2022-05-12 Sale |
2022-05-16 8:54 pm |
Cullinan Oncology Inc. | CGEM | F2 Vision SCS Jovan-Embiricos Morana 10% Owner |
418,738 | $9.6619 | $4,045,791 | 4,532,867 (Indirect Direct) |
View |
| 2022-05-12 Purchase |
2022-05-16 7:34 pm |
Cullinan Oncology Inc. | CGEM | BVF PARTNERS L P BIOTECHNOLOGY VALUE FUND L P BVF I GP LLC BIOTECHNOLOGY VALUE FUND II LP BVF II GP LLC Biotechnology Value Trading Fund OS LP BVF Partners OS Ltd. BVF GP HOLDINGS LLC BVF INC LAMPERT MARK N 10% Owner |
1,109,900 | $9.0674 | $10,063,937 | 319,415 (Direct) |
View |
| 2022-04-01 Purchase |
2022-04-05 6:45 pm |
Cullinan Oncology Inc. | CGEM | BVF PARTNERS L P BIOTECHNOLOGY VALUE FUND L P BVF I GP LLC BIOTECHNOLOGY VALUE FUND II LP BVF II GP LLC Biotechnology Value Trading Fund OS LP BVF Partners OS Ltd. BVF GP HOLDINGS LLC BVF INC LAMPERT MARK N 10% Owner |
276,000 | $10.75 | $2,966,972 | 2,497,911 (Direct) |
View |
| 2021-10-18 Sale |
2021-10-20 4:30 pm |
Cullinan Oncology Inc. | CGEM | Michaelson Jennifer See Remarks |
4,000 | $21.42 | $85,669 | 240,889 (Direct) |
View |
| 2021-10-15 Sale |
2021-10-18 4:15 pm |
Cullinan Oncology Inc. | CGEM | Trigilio Jeffrey Chief Financial Officer |
8,000 | $25 | $200,000 | 232,141 (Direct) |
View |
| 2021-10-15 Sale |
2021-10-18 4:15 pm |
Cullinan Oncology Inc. | CGEM | Zawel Leigh See Remarks |
19,574 | $25 | $489,350 | 37,285 (Direct) |
View |
| 2021-10-07 Sale |
2021-10-12 4:30 pm |
Cullinan Oncology Inc. | CGEM | Zawel Leigh See Remarks |
1,079 | $25 | $26,975 | 56,859 (Direct) |
View |
| 2021-09-20 Sale |
2021-09-21 4:30 pm |
Cullinan Oncology Inc. | CGEM | Michaelson Jennifer See Remarks |
4,000 | $24.51 | $98,048 | 244,889 (Direct) |
View |
| 2021-09-20 Sale |
2021-09-21 4:30 pm |
Cullinan Oncology Inc. | CGEM | Zawel Leigh See Remarks |
7,468 | $25.16 | $187,895 | 57,938 (Direct) |
View |
| 2021-09-16 Sale |
2021-09-20 5:31 pm |
Cullinan Oncology Inc. | CGEM | UBS Oncology Impact Fund L.P. Oncology Impact Fund (Cayman) Management L.P. BioImpact Capital LLC 10% Owner |
3,124 | $29.06 | $90,783 | 7,648,268 (Direct) |
View |
| 2021-09-16 Sale |
2021-09-20 5:30 pm |
Cullinan Oncology Inc. | CGEM | GADICKE ANSBERT Director 10% Owner |
3,556 | $29.06 | $103,337 | 7,892,819 (Indirect Direct) |
View |
| 2021-09-14 Sale |
2021-09-16 4:45 pm |
Cullinan Oncology Inc. | CGEM | UBS Oncology Impact Fund L.P. Oncology Impact Fund (Cayman) Management L.P. BioImpact Capital LLC 10% Owner |
13,531 | $29.17 | $394,635 | 7,651,392 (Direct) |
View |
| 2021-09-14 Sale |
2021-09-16 4:44 pm |
Cullinan Oncology Inc. | CGEM | GADICKE ANSBERT Director 10% Owner |
15,401 | $29.17 | $449,174 | 7,896,375 (Indirect Direct) |
View |
| 2021-09-09 Sale |
2021-09-13 6:24 pm |
Cullinan Oncology Inc. | CGEM | UBS Oncology Impact Fund L.P. Oncology Impact Fund (Cayman) Management L.P. BioImpact Capital LLC 10% Owner |
23,253 | $29.23 | $679,738 | 7,664,923 (Direct) |
View |
| 2021-09-09 Sale |
2021-09-13 6:22 pm |
Cullinan Oncology Inc. | CGEM | GADICKE ANSBERT Director 10% Owner |
26,468 | $29.23 | $773,720 | 7,911,776 (Indirect Direct) |
View |
| 2021-09-08 Sale |
2021-09-09 4:15 pm |
Cullinan Oncology Inc. | CGEM | Baeuerle Patrick See Remarks |
11,000 | $28.45 | $312,950 | 581,548 (Indirect Direct) |
View |
| 2021-09-08 Sale |
2021-09-09 4:15 pm |
Cullinan Oncology Inc. | CGEM | Trigilio Jeffrey Chief Financial Officer |
15,000 | $28.48 | $427,153 | 240,141 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2022-06-22 Option Award |
2022-06-23 6:16 pm |
N/A 2032-06-21 |
Cullinan Oncology Inc. | CGEM | Rosenberg Anthony Director |
16,475 | $0 | 16,475 (Direct) |
View |
| 2021-09-16 Option Award |
2022-03-25 7:35 pm |
N/A 2031-09-15 |
Cullinan Oncology Inc. | CGEM | Ebeling Thomas Director |
7,800 | $0 | 7,800 (Direct) |
View |
| 2021-09-16 Option Award |
2022-03-25 7:34 pm |
N/A 2031-09-15 |
Cullinan Oncology Inc. | CGEM | Rosenberg Anthony Director |
7,800 | $0 | 7,800 (Direct) |
View |
| 2021-09-16 Option Award |
2022-03-25 7:33 pm |
N/A 2031-09-15 |
Cullinan Oncology Inc. | CGEM | Webster Stephen W Director |
7,800 | $0 | 7,800 (Direct) |
View |
| 2021-09-16 Option Award |
2022-03-25 7:32 pm |
N/A 2031-09-15 |
Cullinan Oncology Inc. | CGEM | GADICKE ANSBERT Director 10% Owner |
7,800 | $0 | 7,800 (Direct) |
View |
| 2021-09-16 Option Award |
2022-03-25 7:32 pm |
N/A 2031-09-15 |
Cullinan Oncology Inc. | CGEM | Jovan-Embiricos Morana Director |
7,800 | $0 | 7,800 (Direct) |
View |
| 2022-03-05 Option Award |
2022-03-07 9:50 pm |
N/A 2025-03-05 |
Cullinan Oncology Inc. | CGEM | AHMED NADIM President and CEO |
215,000 | $0 | 215,000 (Direct) |
View |
| 2022-02-28 Option Award |
2022-03-02 7:05 pm |
N/A 2032-02-27 |
Cullinan Oncology Inc. | CGEM | Jones Jeffrey Alan Chief Medical Officer |
215,000 | $0 | 215,000 (Direct) |
View |
| 2022-03-01 Option Award |
2022-03-02 7:05 pm |
N/A 2032-02-29 |
Cullinan Oncology Inc. | CGEM | Martin Anne-Marie Director |
36,880 | $0 | 36,880 (Direct) |
View |
| 2022-02-11 Option Award |
2022-02-15 4:55 pm |
N/A 2032-02-10 |
Cullinan Oncology Inc. | CGEM | Michaelson Jennifer Chief Development Officer |
85,500 | $0 | 108,411 (Direct) |
View |
| 2022-02-11 Option Award |
2022-02-15 4:48 pm |
N/A 2032-02-10 |
Cullinan Oncology Inc. | CGEM | Keane Raymond T Chief Legal Officer |
67,500 | $0 | 69,124 (Direct) |
View |
| 2022-02-11 Option Award |
2022-02-15 4:48 pm |
N/A 2032-02-10 |
Cullinan Oncology Inc. | CGEM | Baeuerle Patrick See Remarks |
112,500 | $0 | 453,934 (Direct) |
View |
| 2022-02-11 Option Award |
2022-02-15 4:47 pm |
N/A 2032-02-10 |
Cullinan Oncology Inc. | CGEM | Zawel Leigh See Remarks |
97,500 | $0 | 134,785 (Direct) |
View |
| 2022-02-11 Option Award |
2022-02-15 4:43 pm |
N/A 2032-02-10 |
Cullinan Oncology Inc. | CGEM | Savill Corrine Acting Chief Business Officer |
49,500 | $0 | 242,615 (Direct) |
View |
| 2022-02-11 Option Award |
2022-02-15 4:43 pm |
N/A 2032-02-10 |
Cullinan Oncology Inc. | CGEM | Trigilio Jeffrey Chief Financial Officer |
112,500 | $0 | 114,750 (Direct) |
View |
| 2022-01-11 Other |
2022-01-13 5:22 pm |
N/A N/A |
Cullinan Oncology Inc. | CGEM | F2 Vision SCS Jovan-Embiricos Morana 10% Owner |
1,187,734 | $0 | 2,912,345 (Direct) |
View |
Ownership |
2022-01-10 5:40 pm |
N/A N/A |
Cullinan Oncology Inc. | CGEM | BVF PARTNERS L P BIOTECHNOLOGY VALUE FUND L P BVF I GP LLC BIOTECHNOLOGY VALUE FUND II LP BVF II GP LLC Biotechnology Value Trading Fund OS LP BVF Partners OS Ltd. BVF GP HOLDINGS LLC BVF INC LAMPERT MARK N 10% Owner |
0 | $0 | 5,278,527 (Direct) |
View |
| 2021-10-18 Option Award |
2021-10-20 4:35 pm |
N/A 2031-10-17 |
Cullinan Oncology Inc. | CGEM | AHMED NADIM President and CEO |
2,710,000 | $0 | 2,710,000 (Direct) |
View |
| 2021-10-18 Exercise |
2021-10-20 4:30 pm |
N/A 2030-10-28 |
Cullinan Oncology Inc. | CGEM | Michaelson Jennifer See Remarks |
4,000 | $0 | 240,889 (Direct) |
View |
| 2021-10-18 Exercise |
2021-10-20 4:30 pm |
N/A N/A |
Cullinan Oncology Inc. | CGEM | Michaelson Jennifer See Remarks |
4,000 | $4.3 | 240,889 (Direct) |
View |
| 2021-10-15 Exercise |
2021-10-18 4:15 pm |
N/A 2030-10-28 |
Cullinan Oncology Inc. | CGEM | Trigilio Jeffrey Chief Financial Officer |
8,000 | $0 | 232,141 (Direct) |
View |
| 2021-10-15 Exercise |
2021-10-18 4:15 pm |
N/A N/A |
Cullinan Oncology Inc. | CGEM | Trigilio Jeffrey Chief Financial Officer |
8,000 | $4.3 | 232,141 (Direct) |
View |
| 2021-09-20 Exercise |
2021-09-21 4:30 pm |
N/A 2030-10-28 |
Cullinan Oncology Inc. | CGEM | Michaelson Jennifer See Remarks |
4,000 | $0 | 244,889 (Direct) |
View |
| 2021-09-20 Exercise |
2021-09-21 4:30 pm |
N/A N/A |
Cullinan Oncology Inc. | CGEM | Michaelson Jennifer See Remarks |
4,000 | $4.3 | 244,889 (Direct) |
View |
| 2021-09-08 Exercise |
2021-09-09 4:15 pm |
N/A 2030-10-28 |
Cullinan Oncology Inc. | CGEM | Baeuerle Patrick See Remarks |
11,000 | $0 | 581,548 (Direct) |
View |
| 2021-09-08 Exercise |
2021-09-09 4:15 pm |
N/A N/A |
Cullinan Oncology Inc. | CGEM | Baeuerle Patrick See Remarks |
11,000 | $4.3 | 581,548 (Direct) |
View |
| 2021-09-08 Exercise |
2021-09-09 4:15 pm |
N/A 2030-10-28 |
Cullinan Oncology Inc. | CGEM | Trigilio Jeffrey Chief Financial Officer |
15,000 | $0 | 240,141 (Direct) |
View |
| 2021-09-08 Exercise |
2021-09-09 4:15 pm |
N/A N/A |
Cullinan Oncology Inc. | CGEM | Trigilio Jeffrey Chief Financial Officer |
15,000 | $4.3 | 240,141 (Direct) |
View |